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Abstract
Background: Urinary tract infection (UTI) is one of the most common infectious diseases at the community level. In
order to assess the adequacy of the empirical therapy, the prevalence and the resistance pattern of the main
bacteria responsible for UTI in the community (in Aveiro, Portugal) was evaluated throughout a ten-year period.
Methods: In this retrospective study, all urine samples from patients of the District of Aveiro, in ambulatory regime,
collected at the Clinical Analysis Laboratory Avelab during the period 2000–2009 were analysed. Samples with more
than 105 CFU/mL bacteria were considered positive and, for these samples, the bacteria were identified and the
profile of antibiotic susceptibility was characterized.
Results: From the 155597 samples analysed, 18797 (12.1%) were positive for bacterial infection. UTI was more
frequent in women (78.5%) and its incidence varied with age, affecting more the elderly patients (38.6%). Although
E. coli was, as usual, the most common pathogen implicated in UTI, it were observed differences related to the
other bacteria more implicated in UTI relatively to previous studies. The bacteria implicated in the UTI varied with
the sex of the patient, being P. aeruginosa a more important cause of infection in men than in women. The
incidence of the main bacteria changed over the study period (P. aeruginosa, Klebsiella spp and Providencia spp
increased and Enterobacter spp decreased). Although E. coli was responsible for more than an half of UTI, its
resistance to antibiotics was low when compared with other pathogens implicated in UTI, showing also the lowest
percentage of multidrug resistant (MDR) isolates (17%). Bacteria isolated from females were less resistant than those
isolated from males and this difference increased with the patient age.
Conclusions: The differences in sex and age must be taken into account at the moment of empirical prescription
of antimicrobials. From the recommended antimicrobials by the European Association of Urology guidelines, the
first line drugs (pivmecillinam and nitrofurantoin) and the alternative antibiotic amoxicillin-clavulanic acid (AMX-
CLA) are appropriate to treat community-acquired UTI, but the fluoroquinolones should not be suitable to treat
male infections and the trimethoprim-sulfamethoxazole (SXT) shall not be used in the treatment of UTI at this level.
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Background
The antimicrobials misuse in clinical medicine has led to
an increase of the microbial resistance and the consequent
spread of bacterial resistant strains is a serious public
health problem. Urinary tract infection (UTI) is one the
most common infectious diseases of the community and
also of the hospital settings, resulting in high rates of mor-
bidity and high economic costs associated with its treat-
ment [1-3]. Uncomplicated UTI occurs in patients without
any anatomic or functional abnormality in the urinary
tract and may reach, on average, 6.1 days of symptoms, 2.4
days of restricted activity and 0.4 bed days [4-6]. Uncom-
plicated cystitis (infection of bladder) is the most common
UTI and is responsible for 95% of all symptomatic urinary
tract infection [7].
Some studies carried out in the community have shown
that uropathogens such as Escherichia coli (46.4 - 74.2%),
Klebsiella spp (6.0 - 13.45%), Proteus spp (4.7 - 11.9%) and
Enterococcus spp (5.3 - 9.54%) represent the main causes of
UTI [2,8-16]. E. coli has been indicated as the most fre-
quent uropathogen involved in the community-acquired
UTI [10,13,16,17] due to the fact of belonging to the nor-
mal flora of the human intestine and therefore easily colon-
izing the urinary tract. Some strains of E. coli isolated from
sexually active patients matched with faecal isolates from
their partners, which indicate that the ITU can be sexually
transmitted [18]. Community-acquired urinary tract infec-
tions are mainly uncomplicated, colonizing preferably the
bladder and causing cystitis [18,19]. However, E. coli may
ascend through the ureters to the kidneys and cause more
severe infections such as pyelonephritis [18,19]. The bacter-
ium Pseudomonas aeruginosa is emerging as an opportun-
istic pathogen of UTI in the community and has been
associated to 10.7 - 25% of cases [3,10,11,20-22].
The early treatment of UTI decreases the rate of morbid-
ity, implying that in most cases antimicrobial therapy be
prescribed empirically [10]. In order to administer an
appropriate empirical therapy it is crucial to know the
main bacteria usually involved in the urinary tract infection
as well as their respective antimicrobial resistance pattern
[15,23]. This procedure allows controlling the increase of
antimicrobial resistance and the spread of resistant bacterial
strains that represent a public health problem worldwide.
The treatment of acute uncomplicated cystitis recom-
mended by the guidelines of the European Association of
Urology (EAU) include fosfomycin, trometamol, pivmecilli-
nam (a penicillin), nitrofurantoin (a nitrofuran) as first-line
therapy and, as an alternative therapy, fluoroquinolones,
cepodoxime proxetil, the sulfonamides SXT and trimetho-
prim, if the local resistance is less than 20% [24,25]. These
recommendations for UTI empiric treatment should be
adjusted taking into account the geographical location of
the patient, age, sex and other diseases [26]. According the
ARESC, an international survey on the antimicrobial
resistance of pathogens implicated in uncomplicated UTIs
[27], E. coli showed high resistance to the sulfonamide SXT
(29.4%) and reduce resistance to nitrofurantoin (1.6%) and
to fluoroquinolone ciprofloxacin (8.1%) in nine European
countries and in Brazil.
Unfortunately there are few publications about the main
uropathogens implicated in community-acquired UTI and
their antimicrobial resistance pattern, when compared
with UTI acquired at hospital level. This information is
very important and reflects changes over the years, which
implies a periodic monitorization in order to decrease the
number of therapeutic failures [15,26,28].
The main objective of this study was to evaluate the
prevalence and the antimicrobial resistance pattern of the
main bacteria responsible for urinary tract infection in the
community of Aveiro District (Portugal), throughout a ten
year period, in order to establish an appropriate empirical
therapy.
Methods
Samples
In this retrospective study, all urine samples from patients
of the District of Aveiro, in ambulatory regime, collected at
the Clinical Analysis Laboratory Avelab (Aveiro, Portugal)
during the period 2000–2009 were analysed. Samples were
collected from patients presenting clinical symptoms of
urinary tract infection, from UTI post-treatment patients
and pregnant women.
For each patient the collection date, age, sex, urine cul-
ture results, identification of the bacterial strain responsible
for UTI and the correspondent Antimicrobial Susceptibility
Test (AST) results were registered. The study was ap-
proved by the Ethical Committee of the Clinical Analysis
Laboratory Avelab, specifically by Doctors Alberto Ferreira
Neves, António Rodrigues and Maria Teresa Raposo.
Sampling
Early urine sample was collected, using the Avelab
Laboratory protocol, by midstream clean-catch technique
after patient daily hygiene. The initial and the end portion
of the micturition were discarded and the middle jact was
collected directly into the sterile recipient. For children up
to two years the urine sample was collected using a collec-
tion bag that was adhered to the skin surrounding the ur-
ethral area. The collection bag was controlled every fifteen
minutes and after micturition the bag was removed, closed
and stored at 4°C until processing. The urine samples
were analyzed within one hour after collection. When this
procedure was not possible the urine samples were stored
at 4°C and processed until 24 h after collection.
Microscopic examination
The samples of urine were homogenized and transferred
to a conical tube of 10 mL. The urine was centrifuged at
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2500 rpm for seven minutes and the supernatant was dec-
anted. The pellet was homogenized and mounted on
slides that were directly examinated or stained by the
Gram technique.
Urine culture
The urine samples were inoculated in different culture
media. A calibrated loop of 1 μL was dipped in vertical pos-
ition in the urine sample and the loop was used to inoculate
the plates using the streak plate method. Gram negative
bacilli, were detected using the Levine medium (Biokar
Diagnostics, BK056HA). For Gram positive cocci, the urine
samples were spread in Mannitol Salt Agar (Biokar
Diagnostics, BK030HA) for the detection of Staphylococcus
spp, in Bile Esculin Agar (BD BBL, 212205) for the detec-
tion of E. faecalis and in Blood Agar (Biomérieux, 43041)
for the detection of Streptococcus spp. The Petri plates were
incubated at 37°C during 24–72 hours, depending on the
microorganism. The plates of Blood Agar were incubated
in 5-10% CO2 atmosphere. After incubation, the urine cul-
tures were classified as negative, positive and contaminated.
The samples were classified as contaminated when poly-
morphic bacterial growth (growth of two or more bacterial
species) was observed (exclusion criterium). The urine cul-
tures were classified as negative when bacterial growth was
lower than 103 CFU/mL (exclusion criterium). When mo-
nomorphic bacterial growth was higher than 105 CFU/mL
the culture was classified as positive (inclusion criterium)
and, for these cases, the AST was performed. The AST was
also performed when the result of urine culture was
between 104 and 105 CFU/mL.
Identification of bacterial isolates
Additional biochemical tests were done when the urine
culture was positive. These tests were performed based on
the morphology of the isolated bacteria and on the results
of the microscopic examination of the Gram-stained
smear. The Enterobacteriaceae were differentiated using
the the Kligler (BD BBL, 211317), Tryptone (BD BBL,
264410), Simmons Citrate (BD BBL, 211620) and Urea
(Oxoid, CM0053) media. Proteus mirabilis was distin-
guished from the Proteus vulgaris by the indol test. The
coagulase test (Biomérieux, Slidex Staph plus, 73115) was
used to differentiate Staphylococcus aureus from the other
Staphylococcus. Staphylococcus epidermidis (novobiocin-
sensitive) was differentiated from Staphylococcus saprophyticus
(novobiocin-resistant) using the novobiocin susceptibility
test (BD BBL Sensi-Disc, 231314). The catalase test was
used to distinguish Staphylococcus spp from Enterococcus
faecalis and Streptococcus spp. The oxidase test (BD BBL,
231746) was used to identify Pseudomonaceae. The uro-
pathogen Pseudomonas aeruginosa was identified by pro-
duction of diffusible pigments on Mueller-Hinton Agar
(Biokar Diagnostics, BK048HA) and for a grape-like odour
released [29].
Reference strains Escherichia coli ATCC 25922, Pseudo-
monas aeruginosa ATCC 27853, Staphylococcus aureus
ATCC 29123 and Staphylococcus epidermidis ATCC
12228 were used as positive control.
Antimicrobial susceptibility test
The AST was performed using the modified Kirby-Bauer
disk diffusion method. A bacterial suspension in physio-
logical saline solution, with a turbidity of 0.5 on McFarland
scale, was prepared by peaking up 1–2 colonies from pure
cultures. The suspension was spread platted using a swab,
on Mueller-Hinton Agar. Antimicrobial-impregnated disks
were (BD BBL, Sensi-Disc) placed onto the cultures
medium surface using an automated disk dispenser. For
the Enterobacteriaceae, the antibiotics amoxicillin, ceph-
radine, cefuroxime, amoxicillin-clavulanic acid, amikacin,
gentamicin, ciprofloxacin, trimethoprim-sulfamethoxazole
and nitrofurantoin were tested. For Enterococcus spp
and Streptococcus spp penicillin, imipenem, amoxicillin-
clavulanic acid, gentamicin, ciprofloxacin, nitrofurantoin
and vancomycin were used. For Staphylococcus spp,
penicillin, cephradine, amoxicillin-clavulanic acid, genta-
micin, ciprofloxacin, nitrofurantoin and vancomycin. For
Pseudomonas spp piperacillin, cefepime, aztreonam, imi-
penem, amikacin, gentamicin and ciprofloxacin were
tested. The plates were incubated at 37°C for 18–24 hours.
After incubation, the antimicrobials efficacy was deter-
mined by measuring the diameter of the zones of inhi-
bition [30]. Bacterial strains were classified as susceptible
(S), intermediate (I) or resistant (R) according the dia-
meter of the inhibition zone [30].
Statistical analysis
The data were treated using the Statistical Package for the
Social Sciences (SPSS) 16.0 for Windows. The significant
level established was 0.05. The normality of data, ho-
mogeneity and independence of variance were checked
before analysis. As most of the variables failed these statis-
tical method assumptions, the non-parametric Mann–
Whitney and Kruskal-Wallis tests, were used. To simplify
the statistical treatment it were selected the main bacteria
responsible for UTI, namely Escherichia coli, Staphylococcus
aureus, Proteus mirabilis, Klebsiella spp, Enterococcus fae-
calis, Proteus vulgaris, Pseudomonas aeruginosa, Enterobac-
ter spp, Staphylococcus epidermidis and Providencia spp. All
of these selected bacteria were responsible for at least 1%
of the observed infections, which corresponded to 93.5%
of all positives urine cultures. The bacteria responsible for
less than 1% of UTI, account for 6.5% of observed
infections.
To analyze the antibiotic resistance pattern of the main
bacteria implicated in UTI, preliminary studies were
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Table 1 Incidence of the main ten bacteria implicated in urinary tract infection throughout the study period
Children Adolescents Young adults Adults Elderly Isolates
in the
10
years
(%)a
Male
(%)a
Female
(%)a
MDR
(%)0-12 years 13-18 years 19-34 years 35-64 years > 65 years
Bacteria Totala Mb Fb Totala Mb Fb Totala Mb Fb Totala Mb Fb Totala Mb Fb (N=
18797)
(N=
3641)
(N=
13939)(N =
615)
(n
=137)
(n=478) (N=
340)
(n=46) (n=294) (N=
4113)
(n=322) (n=3791) (N=
5810)
(n=1240) (n=4570) (N=
6702)
(n=1896) (n=4806)
Enterobacter
sp
1.3 0.3 1.0 2.1 1.2 0.9c 2.0 0.3 1.7c 1.7 0.4 1.3 2.5d 1.3 1.1c 1.9 3.6c 1.7 60.8
E. faecalis 3.1 0.5 2.6 3.2 0.3 2.9 3.8 0.4 3.4 3.6 0.8 2.8 4.3 1.8 2.5c 3.6 5.2c 3.5 28.1
E. coli 71.1 15.8 55.3 65.9 5.9 60a 69.9 4.7 65.3c 71.4d 14.2 57.3c 66.2 14.9 51.4c 64.5 58.5 71.7c 17.0
Klebsiella sp 1.8 0.5 1.3 4.1 1.8 2.4a 3.1 0.4 2.7c 4.0 1.1 2.9c 6.3d 2.1 4.1c 4.3 6.3c 4.1 35.0
P. mirabilis 7.6d 2.8 4.9c 4.7 1.2 3.5 5.2 0.7 4.6c 4.7 1.0 3.7 4.8 1.6 3.3 4.7 5.8c 4.8 50.3
P. vulgaris 2.4 0.8 1.6 3.2 0.6 2.6 2.5 0.2 2.3 2.6 0.8 1.8c 3.3 0.9 2.3 2.7 3.5c 2.7 95.4
Providencia
sp
2.0 0.3 1.6 2.1 0.3 1.8 1.8 0.1 1.6 1.7 0.3 1.4 1.9 0.6 1.3 1.7 1.8 1.8 95.3
P.
aeruginosa
1.5 0.2 1.3 1.5 0.3 1.2 1.3 0.3 0.9c 1.8 0.9 0.9c 4.2d 2.2 2.0c 2.4 5.9c 1.7 24.7
S. aureus 5.5 0.8 4.7 11.5d 1.8 9.7 8.2 0.6 7.6 6.5 1.4 5.1 5.0 2.2 2.8c 6.0 7.2c 6.2 18.8
S.
epidermidis
3.7d 0.3 3.4 1.8 0.3 1.5 2.1 0.1 2.0 2.0 0.5 1.5 1.6 0.7 0.9c 1.8 2.1 1.9 22.9
Total of UTI
(%)
3.5 0.8 2.7 1.9 0.3 1.6 23.1 1.9 21.2 32.8 7.2 25.6 38.6 11.3 27.3 21.5 78.5
The incidence of UTI by sex, age group and multidrug resistance percentage.
N total number of bacteria for each age group; n: total number of bacteria for each sex; aPercentage determined in relation to N; bPercentage determined in relation to n; cstatistically significant differences of
frequency between sex; dstatistically significant differences between age groups; M male, F female, MDR multidrug resistant.
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Figure 1 Incidence of the main bacteria implicated in UTI by sex during the study period.
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performed to identify the most frequently used antimicro-
bials for each uropathogen, including in the study, the
antimicrobials that were used in more than 85% of the
cases. Uropathogens resistant to three or more antimicro-
bial classes were considered MDR [31].
Results
From the 155597 samples analysed, 120691 (77.6%) were
performed on female patients and 34898 (22.4%) on
males, with an age range of 0 to 99 years. The middle-
aged adults represented the age group that carry out more
analysis, 54466 (35%), followed by young adults 51519
(33.1%), elderly patients 38455 (24.7%), children 7040
(4.5%) and adolescents 4117 (2.6%). From the 155597
urine samples, 18797 (12.1%) of the patients had urinary
tract infection.
Characterization of patients with bacterial UTI
The age of patients with bacterial UTI ranged from 3 to
99 years, with a mean age of 54 years. The average age of
female patients with UTI was 51 years, lower than that of
the males, 61 years. From the 18797 positive bacterio-
logical tests, 4043 (21.5%) were from male patients and
14754 (78.5%) from female patients (Table 1). The elderly
was the age group most affected by UTI with a frequency
of 38.6% (27.3% corresponding to female and 11.3% to
male patients) and the adolescents had the lowest fre-
quency of UTI, 1.9% (1.6% for females and 0.3% for
males). With the exception of the adolescents group, uri-
nary tract infection increased with age (Table 1). A higher
prevalence of infections in females for the all age groups
was observed (Table 1).
Bacteria implied in UTI
The ten bacteria more implicated in the UTI (each of them
implicated at least in 1% of the UTI) in the period of ten
years, represented annually more than 90% of the bacterial
isolates. In 2001, the main bacteria reached the higher
percentage, representing 98.6% of the total and in 2005 the
lowest percentage, representing 91.6% of the isolates.
The predominant agents of UTI were successively
Escherichia coli (64.5%), Staphylococcus aureus (6.0%),
Proteus mirabilis (4.7%), Klebsiella spp (4.3%), Enterococcus
faecalis (3.6%), Proteus vulgaris (2.7%), Pseudomonas
aeruginosa (2.4%), Enterobacter spp (1.9%), Staphylococcus
epidermidis (1.8%) and Providencia spp (1.7%) (Table 1).
Significant (Kruskal-Wallis test, ρ < 0.05) changes in the
main bacteria responsible for UTI were observed during
the study period. In general, the incidence of P. aeruginosa,
Providencia spp and Klebsiella spp increased and the inci-
dence of Enterobacter spp decreased (Figure 1). Despite
the differences in bacterial etiology along the year period,
E. coli was the pathogen most implicated in UTI through-
out all the study period, followed by S. aureus.
The incidence of the bacteria implicated in UTI in
women was statistically different (Mann–Whitney U test,
p < 0.05) from that causing UTI in men. Although the
bacterium E. coli was the most implicated in UTI in both
sexes, its incidence was higher in female patients (average
71.7%) than in males (average 58.5%) (Table 1). The inci-
dence of Pseudomonas aeruginosa was also different for
male and female patients, corresponding to the fourth
cause of UTI in males and the ninth cause in females,
causing 5.9% and 1.7% of the UTI, respectively (Table 1).
The incidence of the ten main bacterial uropathogens
throughout the study period was, more stable for male
than for female patients and was, in general, higher in
the female patients (Figure 1). However, the incidence of
P. aeruginosa in males was frequently higher than in
female patients. The incidence of Providencia spp and of
Enterobacter spp in the period 2001–2002 was similar in
both sexes.
The most implicated bacteria in UTI in the different age
groups were not statistically different (Kruskal-Wallis test,
p> 0.05) when all the samples were considered (female
and males samples). However, significant differences
(Mann–Whitney U test, p < 0.05) of bacterial aetiology for
all age groups were observed when females and males
were analyzed separately, increasing the significance of the
difference with the patient age (Table 1).
Antimicrobial resistance pattern of the main bacteria
implicated in UTI
The Gram negative bacteria showed higher resistance to
penicillins, quinolones and first-generation cephalosporins
than to the other tested antimicrobials (Table 2). E. coli
was the uropathogen that showed the lowest resistance to
antimicrobials (Table 2). The isolates of Providencia spp,
Proteus vulgaris and Enterobacter spp showed high resis-
tance to several of the tested antimicrobials (Table 2). The
Gram positive bacteria showed also higher resistance to
penicillins and quinolones than to the other tested anti-
biotics. For the other antimicrobial groups resistance was
less than 14%. For glycopeptides, carbapenems and nitro-
furans the resistance was lower than 1.5% (Table 3). The
isolates of S. aureus showed high resistance to penicillin
(average of 55.1%) and to the quinolone lomefloxacin
(average of 21.1%) (Table 3). The isolates of E. faecalis
were the Gram positive bacteria with the highest resist-
ance to the tested antimicrobials (Table 3).
The bacterial resistance, in general, changed significantly
over the study period (Kruskal-Wallis test, p < 0.05) but
E. coli did not show significant changes in the resistance
to the tested antimicrobials (Figure 2). The pattern of re-
sistance of the Gram negative Enterobacteriaceae along
the study period was different from that observed for
P. aeruginosa (Figure 2). The three Gram positive bacteria
showed a decrease in the resistance to the antibiotic
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Table 2 Averaged antimicrobial resistance of the main Gram negative uropathogens for female and male patients
Antimicrobial
group
Antimicrobials E. coli P. mirabilis Klebsiella spp P. vulgaris P. aeruginosa Enterobacter spp Providencia spp
N % M F N % M F N % M F N % M F N % M F N % M F N % M F
Aminoglycosides Amikacin 12048 1.5 1.9 1.4 865 4.3 5.7 3.8 800 2.6 2.6 2.6 492 7.3 6.4 7.6 443 7.9 7.1 8.7 360 7.8 9.1 7.0 307 92.8 89.2 93.8
Gentamicin 12034 3.6 6.3* 3.1 868 5.4 7.1* 4.9 798 7.3 8.4 6.8 487 12.9 12.2 13.2 441 15.2 15.7 14.7 361 10.8 13 9.6 307 93.8 90.8 94.6
Isepamicin 10995 1.3 1.8 1.3 787 3.4 4.6 3.1 707 2.0 2.4 1.8 444 6.3 5.4 6.6 387 8.3 8.2 8.3 348 3.2 4.1 2.7 282 92.9 91.7 93.2
Netilmicin 11976 1.3 1.7 1.2 854 0.9 2.9* 0.3 792 2.5 2.7 2.5 484 5.8 7.3 5.3 443 14.4 15.6 13.4 358 8.7 14.5* 5.3 307 94.5 93.8 94.6
Tobramycin 11999 3.0 4.9* 2.6 860 4.1 7.3* 3.1 793 5.8 8.0* 4.9 494 12.6 14.4 11.9 443 16.5 17.0 16.0 358 14.5 23.1* 9.6 306 94.4 93.8 94.6
Carbapenems Imipenem 11846 0.2 0.4 0.1 846 1.3 2.9* 0.8 785 0.4 0.0 0.5 482 2.9 2.4 3.1 425 2.4 2.0 2.7 337 2.1 4.3* 0.9 308 1.3 3.2 0.8
Cephalosporins 1st G Cefazolin 11919 10.5 15.8* 9.4 862 22.2 31.1* 19.3 766 29.9 37.3* 26.9 484 94.8 97.6 93.8 152 98.0 97.3 98.7 346 96.0 97.6 95.0 311 95.5 92.4 96.3
Cephradine 11994 14.1 19.2* 13.0 862 22.3 30.8* 19.5 788 32.0 38.1 29.6 486 95.9 98.4 95.0 155 98.7 98.7 98.8 360 96.4 97.7 95.6 310 96.8 95.3 97.2
Cephalosporins 2nd
G
Cefoxitin 11954 5.1 7.2* 4.7 860 15.8 20.2* 14.4 781 19.0 23.1 17.3 489 26.8 33.9 24.4 170 97.6 98.8 96.6 353 64.0 74.6* 58.1 308 8.4 19.0* 5.7
Cefuroxime 11933 4.3 6.7* 3.8 863 9.6 12.9* 8.6 781 16.1 22.0* 13.8 481 25.4 32.5* 22.9 165 98.8 98.8 98.8 356 62.4 75* 55.3 317 10.1 24.2* 6.4
Cephalosporins 3rd G Cefodizime 8959 0.4 0.8 0.3 609 1.3 1.3* 1.3 595 2.4 4.2 1.6 320 4.1 3.8 4.1 311 7.7 6.4 8.8 253 8.7 13.5 6.1 269 0.0 0.0 0.0
Ceftazidime 11743 1.2 1.6 1.1 863 5.9 4.8 6.3 776 7.9 12.6* 6.0 487 10.3 12.1 9.6 436 4.1 1.9 6.1 347 13.8 17.6 11.7 310 1.0 1.6 0.8
Ceftibuten 12022 0.9 1.3 0.8 864 3.8 3.9 3.8 791 2.4 1.8 2.6 485 5.8 6.7 5.5 425 26.8 28.2 25.6 355 11.5 15.1* 9.6 313 0.0 0.0 0.0
Cephalosporins 4th Cefepime 11921 0.3 0.3 0.3 859 3.7 2.4 4.1 763 1.6 2.8 1.1 488 4.1 4.8 3.8 420 4.8 5.0 4.5 349 5.7 8.7* 4.0 314 0.0 0.0 0.0
Monobactams Aztreonam 11922 2.9 3.5 2.8 861 15.4 14.6 15.7 775 6.2 6.8 5.9 470 21.5 24.2 20.6 423 5.4 5.5 5.4 329 19.8 19.3 20.0 310 5.2 6.3 4.9
Nitrofurans Nitrofurantoin 11768 6.0 9.0* 5.4 863 95.1 95.7 95.0 768 32.8 39.5* 30.2 483 97.1 100.0* 96.1 — — — — 347 39.5 51.6* 32.6 307 87.3 89.2 86.8
Penicillins Amoxicillin 11943 42.4 50.3* 40.8 863 47.7 55.3* 45.3 372 96.8 99.0 95.9 487 97.9 99.2 97.5 — — — — 359 98.6 99.2 98.3 314 99.0 100.0 98.8
AMX-CLA 11879 7.5 10.3* 6.9 863 11.8 20.1* 9.2 316 81.6 85.1 80.3 486 32.9 41.9* 29.8 — — — — 345 83.2 87.1 81.0 309 18.4 27.7* 16.0
Piperacillin 11749 19.5 24.0* 18.5 832 20.0 24.7 18.5 — — — — 457 37.4 49.6* 33.4 418 24.2 24.1 24.2 335 34.9 45.8* 29.0 300 26.7 33.8 24.7
Pivmecillinam 11546 15.8 20.9* 14.7 812 37.7 44.7* 35.4 707 24.8 32.4* 21.5 450 59.1 71.9* 54.8 — — — — 323 46.7 57.1* 41.2 285 24.2 32.8* 22.0
Quinolones Ciprofloxacin 11952 13.9 22.2* 12.2 865 21.3 35.1* 16.9 784 22.3 32.4* 18.3 484 25.0 36.4* 21.2 440 43.4 45.7 41.4 357 23.8 36.9* 16.3 312 18.3 27.7* 15.8
Lomefloxacin 10634 13.7 22.6* 11.9 765 21.8 33.0* 18.5 641 22.9 34.1* 18.8 420 25.2 38.8* 20.8 349 43.8 46.9 41.2 302 25.2 44.7* 15.1 272 18.8 28.3* 16.4
Norfloxacin 11893 14.2 22.8* 12.3 867 22.8 36.2* 18.6 779 21.7 31.3* 18.0 470 24.9 36.2* 21.2 437 44.9 48.1 42.0 355 26.5 44.2* 16.4 307 19.2 29.7* 16.5
Ofloxacin 11937 14.4 23.0* 12.6 860 22.9 35.9* 18.7 783 22.2 32.3* 18.2 483 26.1 38.2* 21.9 438 45.0 48.3 42.1 356 27.2 44.6* 17.3 310 19.4 29.7* 16.7
Sulfonamides SxT 11907 25.4 33.0* 23.8 831 41.5 55.0* 37.2 776 36.0 41.4 33.8 482 57.3 64.5 54.7 — — — — 356 39.3 56.6* 29.5 303 23.1 30.3 21.1
AMX - CLA Amoxicillin-clavulanic acid, SxT Trimethoprim-Sulfamethoxazole, n total number of bacteria resistant to each antimicrobial, N: total number of bacteria tested against each antimicrobial; — Antimicrobial not
tested, M male patient, F female patient, *statistically significant differences (p-value < 0.05) of antimicrobial resistance between female and male patients.
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penicillin and to sulfonamide SXT (Figure 3). For the two
Staphylococcus it was observed also a decrease in the resist-
ance to the four generations of cephalosporins (Figure 3).
The resistance of the isolates most implicated in UTI in
male patients was statistically different (Mann–Whitney U
test, p< 0.05) from that of female patients. Bacteria iso-
lated from female patients were, on average, resistant to
less than 3 antimicrobials, while the bacteria isolated from
male patients were, on average, resistant to 4 antimicro-
bials. However, for S. epidermidis and P. aeruginosa, no
significant differences between sexes were observed (Tables 2
and 3).
In general, an increase of the bacterial resistance was
observed with the age (Kruskal-Wallis test, p < 0.05). For
E. coli, the resistance to the two antibiotics of first line
choice for uncomplicated UTI, tested in this study was
low, 6% for nitrofurantoin and 15.8% for pivmecillinam.
For the other bacteria implicated in UTI, the resistance to
these two first line antibiotics was higher than that
observed for E. coli with an average of 60% for nitrofuran-
toin and 39% for pivmecillinam. Having into account the
incidence and the values of drug resistance of each bacter-
ium, it was calculated the pondered resistance patterns
according to the uropathogens incidence (multiplying the
bacterium averaged resistance by its incidence) for the
two first line antibiotics indicated to treat UTI (Table 4).
The obtained values were 16% and 15%, respectively, for
pivmecillinam and nitrofurantoin (Table 4).
Relatively to the alternative drugs, the resistance of E. coli
was also low, 14% and 8%, respectively, for the fluoroqui-
nolones and AMX-CLA, but for the SXT the resistance
was higher 25%. The other bacteria presented high values
of resistance for these alternative antibiotics, average of
27%, 31% and 34%, respectively, for fluoroquinolones,
Table 3 Averaged antimicrobial resistance of the main Gram positive uropathogens for female and male patients
Antimicrobials
group
Antimicrobials S. aureus E. faecalis S. epidermidis
N % M F N % M F N % M F
Aminoglycosides Amikacin 1104 5.5 5.8 5.4 — — — — 336 5.1 1.3 6.2
Gentamicin 1116 6.2 7.3 5.9 652 31.7 35.6 30.3 337 5.6 7.7 5.0
Isepamicin 1023 5.4 5.5 5.3 447 62.9 67.2 61.2 314 1.3 0.0 1.6
Netilmicin 1094 3.3 4.3 3.0 — — — — 336 1.5 0.0 1.9
Tobramycin 1107 6.4 8.1 5.9 — — — — 335 6.6 9.0 5.8
Carbapenems Imipenem 1106 2.1 3.9 1.5 672 6.3 5.2 6.7 336 0.0 0.0 0.0
Cephalosporins 1st G Cefazolin 1097 15.6 22.0 13.6 — — — — 324 12.0 10.5 12.5
Cephradine 1083 16.5 24.1* 14.2 — — — — 334 12.3 11.7 12.5
Cephalosporins 2nd G Cefoxitin 1097 16.6 20.2 15.5 — — — — 337 13.1 9.1 14.2
Cefuroxime 1091 15.1 20.7 13.4 — — — — 340 13.5 7.7 15.3
Cephalosporins 3rd G Cefodizime 841 10.8 12.8 10.2 — — — — 245 8.2 6.8 8.6
Ceftazidime 1084 17.1 19.0 16.5 — — — — 336 18.8 11.7 20.8
Ceftibuten 1088 11.1 14.9 10.0 — — — — 339 13.6 7.8 15.3
Cephalosporins 4th G Cefepime 1086 10.7 14.2 9.6 — — — — 338 11.8 9.1 12.6
Glycopeptides Teicoplanin 827 3.1 4.4 2.7 621 4.0 5.7 3.4 233 0.9 0.0 1.1
Vancomycin 777 2.6 3.6 2.2 472 1.1 0.0 1.4 218 0.0 0.0 0.0
Nitrofurans Nitrofurantoin — — — — 651 8.0 7.9 8.0 — — — —
Penicillins AMX-CLA 1107 8.3 15.1* 6.3 665 9.5 9.6 9.4 338 3.0 1.3 3.5
Flucloxacillin 992 16.8 20.3 15.8 — — — — 304 15.8 12.3 16.9
Penicillin 1036 55.1 64.5 52.2 646 59.8 61.6 59.1 315 58.1 45.9 61.8
Quinolones Ciprofloxacin 1103 18.0 33.3* 13.4 260 38.1 53.9* 31.5 331 26.6 32.9 24.8
Lomefloxacin 845 21.1 36.4* 15.8 206 45.1 58.9* 40.0 254 26.4 32.8 24.4
Norfloxacin 1073 18.3 32.9* 13.8 262 40.8 50.0 37.4 326 25.8 30.3 24.4
Ofloxacin 1091 17.8 31.9* 13.5 265 40.4 48.6 37.2 333 25.5 30.3 24.1
Sulfonamides SxT 1075 15.6 22.4* 13.5 609 35.5 45.3* 31.6 328 25.9 29.7 24.8
AMX - CLA Amoxicillin-clavulanic acid, SxT Trimethoprim-Sulfamethoxazole, n total number of bacteria resistant to each antimicrobial, N total number of bacteria
tested against each antimicrobial; — Antimicrobial not tested, M male patient, F female patient, * statistically significant differences (p-value < 0.05) of
antimicrobial resistance between female and male patients.
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Figure 2 Variation of antimicrobial resistance pattern of Gram negative bacteria during the study period.
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AMX-CLA and SXT. Considering the incidence of each
bacterium and the values of its resistance to antibiotics, the
pondered resistance was 17%, 13% and 25%, respectively,
for fluoroquinolones, AMX-CLA and SXT (Table 4). For
the fluoroquinolones the pondered resistance was signifi-
cantly higher (Mann–Whitney U test, p < 0.05) for male
than for female (pondered resistance 26% and 14% for male
and female, respectively).
Multidrug resistant bacteria implicated in UTI
The percentage of MDR isolates varied between 17 and
95.4%. P. vulgaris and Providencia spp were the most com-
mon MDR uropathogens (Table 1). The bacteria more
implicated in UTI, E. coli and S. aureus, showed the lowest
percentage of MDR isolates (17.0 and 18.8%, respectively)
(Table 1). Significant differences (Kruskal-Wallis test,
p < 0.05) in bacterial multidrug resistance were observed
throughout the study period. The MDR bacteria isolates
from female patients were statistically different (Mann–
Whitney U test, p < 0.05) from that observed in bacteria
isolated from male patients. The most implicated bacteria
in UTI were, on average, resistant to a higher number of
antimicrobials classes when isolated from male patients
than from female ones. The incidence of MDR bacteria
were statistically different (Kruskal-Wallis test, p < 0.05)
among the different age groups, in general, an increase in
resistance and in MDR with the patient age was observed.
Discussion
Although E. coli was the most frequent uropathogen
implicated in community-acquired UTI (being implicated
in more than an half of all the UTI), as frequently detected
in other studies [10,13,16,17], significant differences in
relation to the other bacteria involved in the community-
acquired UTI were observed relatively to other studies
performed at the community level. Contrary to other
studies, S. aureus was the second most frequent uropatho-
gen involved in the UTI. Even though S. aureus has been
associated to hospitalized patients that have undergone
catheterization and may be associated to urinary tract
infections [32,33], this bacterium has appeared with high
frequency in the community in individuals who were not
hospitalized or underwent medical procedures such as
dialysis, surgery or catheters. An example is the patients with
atopic dermatitis who are usually colonized by S. aureus,
due to changes in the first line of defence. These indivi-
duals serve as major vectors for its transmission [34,35].
In 1997 it was reported that 29% of healthy adults outside
the hospital environment are colonized by MRSA. Today,
it is known that this value increased to 74% [36]. This type
of colonization is caused by strains of S. aureus dif-
ferent from those found in the hospital environment
and are often referred as community-associated MRSA
(CA-MRSA). Some studies have shown that CA-MRSA
has high potential to become endemic in the community
and that this will have a significant impact on the control
of MRSA in hospitals [37-39]. Portugal is one of the
European countries with MRSA rates higher than 50%
[36] which may explain the higher frequency of this bac-
terium in UTI at the community level relatively to other
countries. Staphylococcus saprophyticus, according to the
literature has been the second most common cause of un-
complicated UTI, causing 5-10% of the UTI, [40,41] but
in this study S. saprophyticus was not among the most
implicated bacteria in UTI.
Although E. coli was the most common uropathogen in
both sexes, its incidence was significantly higher in women
(71.7%) than in men (58.5%). However, P. aeruginosa was
the uropathogen more responsible for the differences
between female and male patients, emerging as the fourth
and ninth causes of infection, respectively. According to
the literature, P. aeruginosa is more frequent in males
due to particular characteristics inherent to the patient,
including sex, previous use of antimicrobials, previous
interventions in the urinary tract and patients with neuro-
genic bladder [42].
Even though it has been stated that factors such as age
might influence the aetiology of urinary tract infection,
[14,43,44] in this study it were not observed significant
differences among the bacteria responsible for these
infections in the different age groups when all samples
were considered. However, significant differences were
observed for all age groups when female and male were
analysed separately and, the differences increasing with
the patient age.
The incidence of the two bacteria more implicated in
UTI was stable during the study period, but the incidence
of some bacteria less implicated in UTI changed signifi-
cantly, P. aeruginosa, Providencia spp and Klebsiella spp
increased and Enterobacter spp decreased. The increase in
the incidence of P. aeruginosa (four times during the study
period) seems to be related with the increase of the patient
average life expectancy, which potentially increases the
hospitalization of elderly patients, increasing the transmis-
sion of bacterial strains between hospital and community,
and not to the increase of bacterial resistance to the anti-
microbials. In fact, the increase in P. aeruginosa was sig-
nificantly higher for the elderly group during the study
period. Despite community-acquired urinary infections
caused by P. aeruginosa are still uncommon, this bacte-
rium should not be ignored, since its incidence is increa-
sing and this pattern of variation has been also observed
in other community-acquired UTI studies [11,45]. The
increase in the incidence of Providencia spp (five times
during the study period) contrarily to P. aeruginosa,
seems to be related with its antibiotic resistance increase.
Although infections caused by this uropathogen are less
frequent, in recent years they have increased essentially
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Figure 3 Variation of antimicrobial resistance pattern the Gram-positive bacteria during the study period.
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due to the production of extended spectrum beta lacta-
mases (ESBL) [46]. In fact, in this study it was observed an
increase over the ten years in the resistance of Providencia
spp to nitrofurantoin, fluoroquinolones and SXT, all anti-
biotics used to treat UTI. The increase in the incidence of
this bacterium does not seem to be related to the increase
of elderly patient hospitalization as its incidence was simi-
lar for all the age groups during the study period. The inci-
dence of Klebsiella spp doubled during the study period,
being this increase more accentuated in the last three years
when its resistance to AMX-CLA and quinolones also
increased. The enhancement can be also related with the
average life expectancy increase as Klebsiella spp was more
frequently isolated in elderly UTI patients as in other com-
munity UTI studies [47,48]. The decrease of Enterobacter
spp incidence (four times) can be related with its anti-
microbial resistance decrease. Another study performed in
the community during a period of seven years showed,
however, that antimicrobial resistance of Enterobacter spp
was stable over the years [49].
Although E. coli was responsible for more than half of
the UTI, its antimicrobial resistance was significantly
lower than that presented by the other bacteria less impli-
cated in UTI. Having into account the incidence of each
bacterium (65% for E. coli and 29.1% for the other bac-
teria) both first line antibiotics choice for uncomplicated
UTI tested in this study (nitrofurantoin and pivme-
cillinam) drugs are suitable for UTI treatment in the
community. Relatively to the alternative therapy drugs,
considering the incidence of each uropathogen, according
to the EAU, the AMX-CLA is appropriate to treat UTI
in the community but fluoroquinolones should not be
suitable to treat male infections and the SXT should be
unsuitable to treat even female infections as the resistance
was higher than the recommended value (<20%) indicated.
The results of antimicrobial resistance indicate that the
choice of empirical antimicrobial therapy should have into
account the sex of the patient. The uropathogens isolated
from male patients presented, on average, resistance to a
higher number of antibiotics (on average 4) than those
isolated from female patients (on average less than 3). This
difference was clearly evident for E. coli, P. mirabilis and
Enterobacter spp which presented significant differences
for at least 15 of the 25 antimicrobials tested (correspon-
ding to 60-70% of the antibiotics). For the other three
Enterobacteriaceae and for E. faecalis, the difference was
also evident (at least for 39% of the tested antibiotics). The
difference between male and female was clearly evident
(with the exception of P. aeruginosa and S. epidermidis)
for the fluoroquinolones indicated by the EAU as alterna-
tive therapy drug. Consequently this antibiotic should be
suitable to treat female infections (resistance <20% for
70% of the bacteria more implicated in UTI) but should
be not appropriate to treat male infection (resistance
>20% for all of the ten bacteria more implicated in UTI).
For P. aeruginosa and S. epidermidis, however, it was
not observed significant differences of bacterial resistance
between sexes for the antibiotics tested, probably due to
the frequent association of these two bacteria with
hospital-acquired infections. Although the pattern of
resistance of P. aeruginosa was not different for both
sexes, as this bacterium is a more important cause of
community-acquired UTI in men than in women, the em-
piric therapy must consider the clinical history for male
patients, such as recent hospitalizations, in order to evalu-
ate if UTI can be due P. aeruginosa, and, in these cases,
Table 4 Pondered bacterial resistance to the antimicrobials recommended for empirical treatment of urinary tract infection
Resistance to first-line therapy Resistance to second-line therapy
Bacteria Incidence (%) PIV (%) PIV (%)1 NIT (%) NIT (%)1 AMX-CLA (%) AMX-CLA (%)1 SXT (%) SXT (%)1 FLU (%) FLU (%)1
E. coli 64.5 15.8 10.2 6.0 3.9 7.5 4.8 25.4 16.4 14.1 9.1
S. aureus 6.0 — — — — 8.3 0.5 15.6 0.9 18.8 1.2
P. mirabilis 4.7 37.7 1.8 95.1 4.5 11.8 0.6 41.5 2.0 22.2 1.1
Klebsiella spp 4.3 24.8 1.1 32.8 1.4 81.6 3.5 36.0 1.5 22.3 1.0
E. faecalis 3.6 — — 8.0 0.3 9.5 0.3 35.5 1.3 41.1 1.5
P. vulgaris 2.7 59.1 1.6 97.1 2.6 32.9 0.9 57.3 1.5 25.3 0.7
P. aeruginosa 2.4 — — — — — — — — 44.3 1.1
Enterobacter spp 1.9 46.7 0.9 39.5 0.8 83.2 1.6 39.3 0.7 25.7 0.5
Snn epidermidis 1.8 — — — — 3.0 0.1 25.9 0.5 26.1 0.5
Providencia 1.7 24.2 0.4 87.3 1.5 18.4 0.3 23.1 0.4 18.9 0.3
Pondered
Resistance (%)
15.9 14.9 12.6 25.2 16.8
The pondered bacterial resistance was determined having into account the incidence and resistance of each bacterium. For the fluoroquinolones the pondered
bacterial resistance by sex was also determined (25.6% for males and 14.3% for females).
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the fluoroquinolones must be avoided. In a similar study
done in the community, the bacterial resistance of E. coli,
Klebsiella spp, Proteus spp, Citrobacter spp and Enterobacter
spp were, in general, higher when the uropathogens
were isolated from male patients [50]. However, Koeijers
et al. [42] showed that the uropathogens responsible for
community-acquired urinary tract infections, namely
caused by E. coli, P. mirabilis and K. pneumoniae had simi-
lar susceptibility patterns in females and males.
In general, it was observed an increase of the bacterial
resistance with the age of the patients. The uropatho-
gens isolated from the elderly group were more resistant
than the isolates from other age groups, which may be
explained by the increase of the number and the du-
ration of hospital admissions with the increasing age of
the patients.
Whereas, in general, the first line drugs and at least one
of the alternative drug used to treat non-complicated
infections, are appropriate for treat community-acquire
UTI which are usually treated at home, to treat more
complicated infections caused, for instance by MDR
strains (frequent in this study), a tailored therapy will be
necessary. For these cases, the carbapenem imipenem, the
third and fourth generation chephalosporins, aminoglyco-
sides and glycopeptides (for Gram negative bacteria)
should be suitable as the bacteria more implicated in
community-acquired UTI do not present high resistance
to these drugs. However, most of these drugs do not exist
in the oral form, involving the inconvenience of parenteral
administration, and are also more expensive than those
indicated for the UTI treatment.
Conclusions
As with the age increase, the differences in the uropatho-
gen incidence between male and female patients increase
and the bacteria isolated from male were, in general, more
resistant to antibiotics when compared with bacteria iso-
lates from female patients, the choice of empirical anti-
microbial therapy should have into account the sex of the
patients.
The results obtained in this study suggest the first line
drugs indicated to treat non-complicated UTI (piv-
mecillinam and nitrofurantoin) as well as the alterna-
tive antibiotic AMX-CLA are appropriate drugs but the
fluoroquinolones should not be suitable to treat male
infections and the SXT antibiotic should not be even be
considered to treat female UTI.
Considering that in this study (1) S. aureus was more
frequent than in other international studies, (2) the bac-
terium S. taphylococcus saprophyticus was less frequent,
(3) the resistance of the main bacterium implicated in
UTI, E. coli, to the fluoroquinolone ciprofloxacin and to
nitrofurantoin was higher than that observed in other
European countries and (4) the bacteria isolated from
male patients were more resistant to most of the antibio-
tics indicated for UTI treatment than those isolated from
females (pattern of variation similar to that observed in
some countries but different from that found in others),
the results of this study cannot be translated to the inter-
national level, confirming the statement of the World
Health Organization that local data on antimicrobial in-
cidence and resistance are essential to define the best
treatment for individual patients, to formulate recommen-
dations for rational antibiotic use and standard treatment
guidelines, ensuring that health-care providers comply
with recommendations.
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